KENACORT Drug Patent Profile

Which patents cover Kenacort, and when can generic versions of Kenacort launch?

Kenacort is a drug marketed by Delcor Asset Corp and is included in two NDAs.

The generic ingredient in KENACORT is triamcinolone. There are two drug master file entries for this compound. Additional details are available on the triamcinolone profile page.

Summary for KENACORT

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	13
DailyMed Link:	KENACORT at DailyMed

Recent Clinical Trials for KENACORT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
I.R.C.C.S. Fondazione Santa Lucia	NA
Sohag University	Phase 4
Assiut University	Phase 4

See all KENACORT clinical trials

US Patents and Regulatory Information for KENACORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Delcor Asset Corp	KENACORT	triamcinolone diacetate	SYRUP;ORAL	012515-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Delcor Asset Corp	KENACORT	triamcinolone	TABLET;ORAL	011283-006	Approved Prior to Jan 1, 1982		DISCN	No	No
Delcor Asset Corp	KENACORT	triamcinolone	TABLET;ORAL	011283-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Delcor Asset Corp	KENACORT	triamcinolone	TABLET;ORAL	011283-008	Approved Prior to Jan 1, 1982		DISCN	No	No
Delcor Asset Corp	KENACORT	triamcinolone	TABLET;ORAL	011283-010	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: June 28, 2026

KENACORT (triamcinolone acetonide) market dynamics and financial trajectory: sales trends, payer drivers, competition, and exclusivity/patent exposure

Executive summary: KENACORT is a corticosteroid brand based on triamcinolone acetonide used for inflammatory and allergic conditions in the U.S. market. In practice, KENACORT’s financial trajectory is constrained by (1) broad generic availability for triamcinolone acetonide formulations, (2) limited life-cycle leverage because most use cases are sustained by older, already-established therapies, and (3) channel/payer pressure that typically drives net price compression as multi-source supply expands. The net effect is usually a shift from “brand growth” to “declining brand remnant” once generics are fully entrenched.

Because KENACORT is used as a brand name across multiple dose forms and geographies (and because “KENACORT” listings vary by NDC and formulation), a complete, accurate financial trajectory requires explicit mapping to the specific U.S. product strength/dosage form and the reporting entity that files the earnings disclosures. With insufficient product-level identifiers, a fully complete and accurate market and financial profile cannot be produced.